New insider activity at Instil Bio ( (TIL) ) has taken place on September 12, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sandeep Laumas, the CFO and CBO of Instil Bio, has recently sold 30,000 shares of the company’s stock, amounting to a total value of $701,667. This transaction highlights a significant movement in the company’s stock holdings by a key executive.
Recent Updates on TIL stock
Instil Bio’s stock has seen recent developments following the announcement by ImmuneOnco Biopharmaceuticals of preliminary efficacy and safety data for their monotherapy ‘2510 in a Phase 1 study. The study, presented at the 2025 World Conference on Lung Cancer, involved patients with previously treated squamous non-small cell lung cancer in China. The results showed a 35.3% objective response rate in efficacy evaluable patients, with the majority of responses in those with negative and low PD-L1 TPS scores. The treatment was generally well tolerated, with manageable low-grade infusion reactions and two Grade 3 VEGF-related adverse events. The promising data for ‘2510, designed for potential best-in-class activity, has been favorably compared to other PD-(L)1xVEGF bispecific class molecules, which may influence analysts’ price target changes due to its potential market impact and successful trial outcomes.
Spark’s Take on TIL Stock
According to Spark, TipRanks’ AI Analyst, TIL is a Underperform.
Instil Bio’s stock faces considerable challenges primarily due to severe financial instability, as evidenced by the absence of revenue and ongoing losses. The technical analysis indicates a bearish trend, with the stock significantly underperforming compared to its moving averages. Additionally, the company’s valuation metrics, including a negative P/E ratio and no dividend yield, further underscore the high risk associated with this investment. These factors combine to give Instil Bio a low overall stock score.
To see Spark’s full report on TIL stock, click here.
More about Instil Bio
YTD Price Performance: 10.08%
Average Trading Volume: 208,195
Technical Sentiment Signal: Hold
Current Market Cap: $160.7M